Navin Fluorine International Limited-$ Q1 FY27 Results

NAVINFLUOR's story for FY27 hinges on execution of three plays: the CDMO wing (contract manufacturing for pharma), the new AHF (anhydrous hydrofluoric acid) plant, and R32 refrigerant capacity expansion. Q4 FY26 delivered a tour—₹938 Cr revenue (+34% YoY), operating EBITDA +80% to ₹321 Cr with 34.2% margins. That was the high watermark. Q1 will be messier: seasonal softness in commodity fluorine (lower demand post-summer), but offset by the CDMO growth trajectory and new asset utilization kick-in. What to expect: a quarter that shows either sustained margin expansion (if CDMO and AHF are being put to work) or profit-taking pressure (if growth stalls while prior plants ramp costs). Street expects the former.

What a good quarter looks like: Revenue in the ₹800–850 Cr band, EBITDA margin above 25% (showing the gearing from prior capacity spend is real), and CDMO keeping the +50% growth momentum. Earmarks: AHF (live now) contribution to gross margin, R32 utilization ramping into mid-year. What a weak quarter looks like: Revenue below ₹780 Cr (demand stumble), margin squeeze below 22% (cost inflation, lower CDMO mix), or CDMO growth stalling below +40% (suggests the new customer pipeline is soft). Either would raise questions about FY27 guidance sustainability.

Full-year FY27 expectations are clear from analyst consensus: ₹3,600–3,800 Cr revenue (27% CAGR vs FY25), 34% EBITDA CAGR, margin in 23–26% range. Q4 FY26 was ₹938 Cr revenue, so Q1–Q3 need to average ~₹870 Cr to hit the midpoint of FY27 guidance. On current form (Q1 FY26 was ₹725 Cr, Q4 was ₹938 Cr), expecting Q1 FY27 in the ₹800–850 band is reasonable. The risk: if commodity prices (fluorine HCFCs, HFCs) roll over or if any customer (e.g., Chemours project, expected to finish by end-June) delays payment or recognition, Q1 could miss low-ball. Odds favor on-plan, but the tape is still thin—watch for any guidance revisions or headwinds flagged on the call.

ICICI Securities (one of the active houses on the name) has pegged a target of ₹7,250, based on 26x FY28E EBITDA, implying they're betting on the CDMO and new capacity story to de-rate commodity fluorine exposure. The consensus has nudged target lower slightly in recent months as FY27 revenue growth assumptions have hardened from 18.7% to ~19%, a sign that the Street is getting more disciplined on the pace but still backing the thesis.

Strong execution across all segments with margin beat (34.2% vs. 30% guided), backed by deep product pipelines (CDMO 30–40 molecules, advanced materials 12-product slate). Key risk: R32 supply oversupply CY27–31, mitigated by contracting strategy (35–45%) and cost-leadership position. Multiple capex projects (₹340+ Cr) are value-accretive if executed; portfolio diversity de-risks single-product exposure.

Analysts pressed hard on R32 oversupply timing, CDMO supply-chain parity vs. competitors, specialty chem pricing sustainability, and capex asset-turn visibility. Management held firm: cost-leadership on R32, 3x asset turn by FY'29 on CDMO capex, portfolio-based navigation on agchem (3 of 5 new molecules patented, pricing power). Candid on CDMO readout failures as normal risk. Minor deflections on DRDO details (confidentiality) and Chemours scaling timeline (15-month window, wait and see).

Score 7/10. Clear strategy articulation; transparent on R32 supply risks, CDMO readout failures, and margin cyclicality. Some deflection on DRDO details (confidentiality claim valid but limits visibility) and Chemours scaling timeline ('wait and see' is cautious). Strong track record: announced HFC/CDMO Phase 1/renewable capex executed on time. Advanced materials phased approach shows discipline. One CDMO readout failure acknowledged as portfolio norm, not glossed over.

Navin Fluorine's consolidated Q1 FY27 print is a clean beat: revenue from operations of ₹1,045.08 Cr grew 44.1% YoY (₹725.40 Cr) and 11.4% QoQ (₹937.71 Cr), while consolidated PAT of ₹243.31 Cr more than doubled YoY (+107.7% from ₹117.16 Cr) and rose 14.4% QoQ (₹212.62 Cr). Both land well above the ₹800-850 Cr revenue and ₹140-160 Cr PAT range our pre-result preview flagged as the on-plan expectation, and above the Street's broader 19-20% FY27 revenue-growth framework — this quarter alone ran more than double that pace. EPS (basic) came in at ₹47.45 versus ₹23.63 a year ago.

Unlike the year-ago and preceding quarters, Q1 FY27 carries no exceptional item on either statement — a clean quarter. That matters for reading the Q4 FY26 base used for QoQ comparison, which included a ₹13.72 Cr (consolidated) reversal of a New Labour Codes provision that flattered that quarter's reported numbers; QoQ growth, while still positive at 14.4% PAT and 11.4% revenue, is running against that inflated base rather than a clean one. On a YoY basis — the primary lens here — margins expanded meaningfully: consolidated OPM (EBITDA margin) rose to 34.17% from 28.51% a year ago, and NPM to 22.53% from 15.85%, both inside or above management's guided ~30% (+/-1-2%) FY27 EBITDA margin band. Sequentially OPM eased slightly from 35.71% in Q4, consistent with that quarter's one-off boost rather than any underlying softness.

The stock went into the print at ₹7,609.5, up 0.8% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.

Management's April guidance called for 'strong double-digit growth' in FY27 on the back of the AHF plant, the Chemours project and new HFC capacity, with CDMO and agrochemical visibility underpinning the outlook — this quarter's 44% YoY revenue growth and margin expansion are directionally consistent with that guide, though the company has not issued a formal quarter-specific number to grade against, and no management press release/MD&A commentary was available in this filing to quote directly. The standalone print is more moderate — revenue ₹694.68 Cr (+27.9% YoY) and PAT ₹190.64 Cr (+68.4% YoY) — a wide gap to the consolidated growth rate, pointing to the foreign CDMO subsidiaries (Manchester Organics, NFIL UK/USA, Navin Fluorine Shanghai) as the larger swing factor this quarter. Alongside the results, the Board approved ₹90 Cr of capex for Advanced Materials adoption capacity at Surat (commissioning targeted Q2 FY28, funded via internal accruals), following the July 30 DRDO partnership for sodium borohydride and a smaller ₹3.63 Cr captive-power SPV investment on July 27 — both consistent with the capex-heavy growth phase management flagged. Street positioning ahead of the print was constructive (27-analyst consensus, BUY-rated, price targets ₹7,316-7,372 versus ~₹7,580 spot), with the debate centred on whether the AHF/CDMO ramp justifies a 27x forward multiple against an 18-20x peer average — this quarter's numbers support that thesis rather than raising red flags.